Serum Glucose-Dependent Insulinotropic Polypeptide (GIP)‎ and Glucagon-Like Peptide-1 (GLP-1)‎ in association with the Risk of Gestational Diabetes: A Prospective Case-Control Study

Abstract EN

Background.

Defects in incretin have been shown to be related to the pathogenesis of type 2 diabetes.

Whether such a deficiency happens in gestational diabetes mellitus (GDM) remains to be confirmed.

We assessed the association of fasting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) with GDM.

We also studied the longitudinal circulation of these peptides during pregnancy and afterwards.

Methods.

53 women with GDM (30 managed with diet only (GDM-diet) and 23 treated with insulin (GDM-insulin)) and 43 pregnant women with normal glucose tolerance (NGDM) were studied, with GIP and GLP-1 levels measured at 24–28 weeks (E1), prior (E2) and after (E3) delivery, and postpuerperium (E4).

Results.

Basal GIP was shown to be low in GDM groups compared to NGDM in E1, and in E4 for GDM-diet.

GLP-1 was low in GDM groups during pregnancy and afterwards.

At E1, serum GIP and GLP-1 were inversely associated with GDM and participants with lower levels of GIP (<0.23 ng/mL) and GLP-1 (<0.38 ng/mL) had a 6 (95% CI 2.5-14.5)- and 7.6 (95% CI 3.0-19.1)-fold higher risk of developing GDM compared with the higher level, respectively.

In the postpuerperium, when there is a drop in β-cell function, participants with previous GDM (pGDM) presented lower GLP-1 (in both GDM subgroups) and lower GIP in GDM-diet subgroup compared to controls.

Conclusion.

There is an independent, inverse association between fasting incretins and higher risk of GDM.

Furthermore, lowered levels of these peptides may play an important role in the abnormality of glucose regulation following pregnancy.